10202017Headline:

Chicago-Land, Illinois

HomeIllinoisChicago-Land

Email Eric Terry Eric Terry on LinkedIn Eric Terry on Twitter Eric Terry on Facebook
Eric Terry
Eric Terry
Attorney • (888) 508-6752

FDA Warns of Risk of Birth Defects With Chronic Diflucan Use

Comments Off

The FDA is warning the public that treatment with chronic, high doses (400-800mg/day) of Diflucan (fluconazole) during the first trimester of pregnancy may be associated with a rare and distinct set of birth defects in infants.

The FDA noted that the risk of birth defects does not appear to be associated with a single, low dose of Diflucan (fluconazole) used to treat vaginal candidiasis (yeast infections)

When is Diflucan prescribed?

  • Fungal infections – including yeast infections of the vagina, mouth, throat, esophagus, abdomen, lungs, blood and other organs,
  • Meningitis caused by fungus
  • Treatment of infections as a result of chemotherapy or radiation therapy prior to a bone marrow transplant.

Currently, the FDA is warning that chronic use of Diflucan could cause:

  • Brachycephaly (flat head syndrome)
  • Abnormal facies
  • Abnormal calvarial development
  • Cleft palate
  • Femoral bowing
  • Think ribs and long bones
  • Arthrogryposis (rare condition with stiff joints and abnormally developed muscles), and
  • Congenital heart disease

Change in Pregnancy Class

As a result of the risk of birth defects, the FDA is changing the pregnancy category from category C to category D. Pregnancy category D means there is positive evidence of human fetal risk based on human data but the potential benefits from use of the drug in pregnant women with serious or life-threatening conditions may be acceptable despites its risks.

The pregnancy category for a single, low dose of fluconazole has not changed and remains category C.